Filament has been issued the first patent for the extraction and standardization of natural psilocybin and intends to further develop its IP portfolio Vancouver, British Columbia, September 1, 2021 – Filament Health Corp. (NEO:FH) (“Filament” or the “Company”), a leading exclusively-natural psychedelic drug development company, today announced that it has filed its 20th patent application in…


Previous articleWhat Is the ‘Collective Unconscious’ and How Can It Help Us Understand Psychedelic Experiences?
Next articleMindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes